The use of an isopyrine-phenylbutazone compound in migraine.
A randomized double-blind study of 40 patients with migraine attacks was carried out to compare an intravenous injection of isopyrine 240 mg plus phenylbutazone 130 mg (Tomanol; Byk-Gulden) with a placebo. Isopyrine is an analgesic with a central sedative action which potentiates the action of phenylbutazone, an inhibitor of prostaglandin biosynthesis and circulation. In 15 patients who received the drug the migraine attack was terminated within 5 minutes of administration, apart from a mild residual headache in 2 cases. No recurrence was reported after 24 hours. The placebo administered to 25 patients gave total relief in 3, a slight improvement of symptoms in 12 and had no effect in 10. Treatment with isopyrine-phenylbutazone compound was based on the immediate central analgesic and sedative action of isopyrine, and the inhibition of the vaso-active action of prostaglandins by phenylbutazone.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000632:Aminopyrine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D010653:Phenylbutazone / Q000008:administration & dosage* / Q000627:therapeutic use; D011897:Random Allocation
D004338:Drug Combinations; D000632:Aminopyrine; C017444:isopyrin; D010653:Phenylbutazone